JMB-HEADER RAS-JOURNALS EIMB Pleiades Publishing

RUS

             

ENG

YearIMPACT-FACTOR
2021  1,540
2020  1,374
2019  1,023
2018  0,932
2017  0,977
2016  0,799
2015  0,662
2014  0,740
2013  0,739
2012  0,637
2011  0,658
2010  0,654
2009  0,570
2008  0,849
2007  0,805
2006  0,330
2005  0,435
2004  0,623
2003  0,567
2002  0,641
2001  0,490
2000  0,477
1999  0,762
1998  0,785
1997  0,507
1996  0,518
1995  0,502
Vol 56(2022) N 5 p. 684-695; DOI 10.1134/S0026893322050144 Full Text

P.O. Vorobyev1, F.E. Babaeva2, A.V. Panova3, J. Shakiba4, S.K. Kravchenko2, A.V. Soboleva1, A.V. Lipatova1*

Oncolytic Viruses in the Therapy of Lymphoproliferative Diseases

1Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, 119991 Russia
2National Medical Research Center for Hematology, Ministry of Health of Russia, Moscow, 125167 Russia
3Vavilov Institute of General Genetics, Russian Academy of Sciences, Moscow, 117971 Russia
4Moscow Institute of Physics and Technology, Dolgoprudny, 141701 Russia

*lipatovaanv@gmail.com
Received - 2022-04-01; Revised - 2022-04-28; Accepted - 2022-05-04

Cancer is a leading causes of death. Despite significant success in the treatment of lymphatic system tumors, the problems of relapse, drug resistance and effectiveness of therapy remain relevant. Oncolytic viruses are able to replicate in tumor cells and destroy them without affecting normal, healthy tissues. By activating antitumor immunity, viruses are effective against malignant neoplasms of various nature. In lymphoproliferative diseases with a drug-resistant phenotype, many cases of remissions have been described after viral therapy. The current level of understanding of viral biology and the discovery of host cell interaction mechanisms made it possible to create unique strains with high oncoselectivity widely used in clinical practice in recent years.

lymphoproliferative diseases, spontaneous remission, oncolytic viruses, clinical trials, virotherapy



JMB-FOOTER RAS-JOURNALS